Animal models of the serotonin syndrome: A systematic review

Boyer, 2005, The serotonin syndrome, N Engl J Med, 352, 1112, 10.1056/NEJMra041867 Ener, 2003, Serotonin syndrome and other serotonergic disorders, Pain Med, 4, 63, 10.1046/j.1526-4637.2003.03005.x Gillman, 1998, Serotonin syndrome: history and risk, Fundam Clin Pharmacol, 12, 482, 10.1111/j.1472-8206.1998.tb00976.x Sternbach, 1991, The serotonin syndrome, Am J Psychiatry, 148, 705, 10.1176/ajp.148.6.705 Isbister, 2005, The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment, Clin Neuropharmacol, 28, 205, 10.1097/01.wnf.0000177642.89888.85 Nisijima, 2007, Neuroleptic malignant syndrome and serotonin syndrome, Progr Brain Res, 162, 81, 10.1016/S0079-6123(06)62006-2 Lane, 1997, Selective serotonin reuptake inhibitor-induced serotonin syndrome: review, J Clin Psychopharmacol, 17, 208, 10.1097/00004714-199706000-00012 Odagaki, 2009, Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics, Curr Drug Safety, 4, 84, 10.2174/157488609787354387 Iqbal, 2012, Overview of serotonin syndrome, Ann Clin Psychiatry, 24, 310 Rusyniak, 2006, Hyperthermic syndromes induced by toxins, Clin Laboratory Med, 26, 165, 10.1016/j.cll.2006.01.007 Gillman, 2005, Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity, Br J Anaesth, 95, 434, 10.1093/bja/aei210 Gillman, 2006, A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action, Biol Psychiatry, 59, 1046, 10.1016/j.biopsych.2005.11.016 Gillman, 2010, Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review, Headache, 50, 264, 10.1111/j.1526-4610.2009.01575.x Silins, 2007, Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk, Aust New Zeal J Psychiatry, 41, 649, 10.1080/00048670701449237 Grubb, 2012, The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature, J Thoracic Cardiovasc Surg, 144, e113, 10.1016/j.jtcvs.2012.07.030 Perry, 2012, Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management, Ann Clin Psychiatry, 24, 155 Rastogi, 2011, Case scenario: opioid association with serotonin syndrome: implications to the practitioners, Anesthesiology, 115, 1291, 10.1097/ALN.0b013e31823940c0 Sporer, 1995, The serotonin syndrome. Implicated drugs, pathophysiology and management, Drug Safety, 13, 94, 10.2165/00002018-199513020-00004 Bijl, 2004, The serotonin syndrome, Netherlands J Med, 62, 309 Gerson, 1980, Motor effects of serotonin in the central nervous system, Life Sci, 27, 1435, 10.1016/0024-3205(80)90368-9 Jacobs, 1976, An animal behavior model for studying central serotonergic synapses, Life Sci, 19, 777, 10.1016/0024-3205(76)90303-9 Kalueff, 2008, Perspectives on genetic animal models of serotonin toxicity, Neurochem Int, 52, 649, 10.1016/j.neuint.2007.08.015 Green, 2008, Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK, Br J Pharmacol, 154, 1583, 10.1038/bjp.2008.207 Glassman, 1969, Potentiation of a monoamine oxidase inhibitor by tryptophan, J Psychiatr Res, 7, 83, 10.1016/0022-3956(69)90013-2 Greenwood, 1975, The acute effects of oral (–)-tryptophan in human subjects, Br J Clin Pharmacol, 2, 165, 10.1111/j.1365-2125.1975.tb01572.x Oates, 1960, Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor, Neurology, 10, 1076, 10.1212/WNL.10.12.1076 Insel, 1982, Possible development of the serotonin syndrome in man, Am J Psychiatry, 139, 954, 10.1176/ajp.139.7.954 Isbister, 2007, Serotonin toxicity: a practical approach to diagnosis and treatment, Med J Australia, 187, 361, 10.5694/j.1326-5377.2007.tb01282.x Ma, 2008, Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats, Eur J Pharmacol, 588, 198, 10.1016/j.ejphar.2008.04.004 Brown, 1996, Pathophysiology and management of the serotonin syndrome, Ann Pharmacother, 30, 527, 10.1177/106002809603000517 Dunkley, 2003, The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity, QJM, 96, 635, 10.1093/qjmed/hcg109 Isbister, 2004, Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose, J Toxicol, 42, 277 Fischer, 1995, Serotonin syndrome in the elderly after antidepressive monotherapy, J Clin Psychopharmacol, 15, 440, 10.1097/00004714-199512000-00009 Gill, 1999, Serotonin syndrome in a child after a single dose of fluvoxamine, Ann Emerg Med, 33, 457, 10.1016/S0196-0644(99)70313-6 Lenzi, 1993, Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage, Pharmacopsychiatry, 26, 100, 10.1055/s-2007-1014351 Brambilla, 2005, Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data, Pharmacopsychiatry, 38, 69, 10.1055/s-2005-837806 Gillman, 2007, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated, Br J Pharmacol, 151, 737, 10.1038/sj.bjp.0707253 Sun-Edelstein, 2008, Drug-induced serotonin syndrome: a review, Exp Opin Drug safety, 7, 587, 10.1517/14740338.7.5.587 Raffa, 1992, Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic, J Pharmacol Exp Ther, 260, 275 Reimann, 1998, Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine, Eur J Pharmacol, 349, 199, 10.1016/S0014-2999(98)00195-2 Parrott, 2002, Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity, Pharmacol Biochem Behav, 71, 837, 10.1016/S0091-3057(01)00711-0 Mueller, 1998, Death by “ecstasy”: the serotonin syndrome, Ann Emerg Med, 32, 377, 10.1016/S0196-0644(98)70018-6 Klys, 2009, Death of a female cocaine user due to the serotonin syndrome following moclobemide-venlafaxine overdose, Forensic Sci Int, 184, e16, 10.1016/j.forsciint.2008.11.010 Malik, 2012, Serotonin syndrome with escitolapram and concomitant use of cocaine: a case report, Clin Med Insights Case Reports, 5, 81, 10.4137/CCRep.S9540 Huether, 1997, Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners, J Neural Transm, 104, 771, 10.1007/BF01285547 Steiner, 1986, Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports, Biol Psychiatry, 21, 1067, 10.1016/0006-3223(86)90287-8 Fernstrom, 2012, Effects and side effects associated with the non-nutritional use of tryptophan by humans, J Nutr, 142, 2236S, 10.3945/jn.111.157065 Levitan, 2000, Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects, J Psychiatry Neurosci, 25, 337 Young, 1991, Use of tryptophan in combination with other antidepressant treatments: a review, J Psychiatry Neurosci, 16, 241 Lambert, 2005, Preclinical neuropharmacology of naratriptan, CNS Drug Rev, 11, 289, 10.1111/j.1527-3458.2005.tb00048.x The, 2007, FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports, MedGenMed, 9, 48 Soldin, 2008, Serotonin syndrome associated with triptan monotherapy, N Engl J Med, 358, 2185, 10.1056/NEJMc0706410 Evans, 2010, FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper, Headache, 50, 1089, 10.1111/j.1526-4610.2010.01691.x Kuehn, 2011, Serotonin Syndrome Update, JAMA, 306, 2661 Ng, 2010, The role of methylene blue in serotonin syndrome: a systematic review, Psychosomatics, 51, 194, 10.1016/S0033-3182(10)70685-X Stanford, 2010, Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium, J Psychopharmacol, 24, 1433, 10.1177/0269881109105450 Packer, 2007, Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid, Am J Psychiatry, 164, 346, 10.1176/ajp.2007.164.2.346b Ramsay, 2007, Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction, Br J Pharmacol, 152, 946, 10.1038/sj.bjp.0707430 Bonetto, 2007, Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum, Cephalalgia: Int J Headache, 27, 1421, 10.1111/j.1468-2982.2007.01430.x Goldberg, 1992, Serotonin syndrome from trazodone and buspirone, Psychosomatics, 33, 235, 10.1016/S0033-3182(92)72007-6 Manos, 2000, Possible serotonin syndrome associated with buspirone added to fluoxetine, Ann Pharmacother, 34, 871, 10.1345/aph.19341 Parks, 2012, Concomitant blockade of 5-HT(1A) receptor and 5-HT transporter: use of the hunter serotonin toxicity criteria in a clinical pharmacology study, Eur Neuropsychopharmacol, 22, 92, 10.1016/j.euroneuro.2011.06.002 Kawano, 2011, [First death case of serotonin syndrome in Japan induced by fluvoxamine and tandospirone], Chudoku kenkyu: Chudoku Kenkyukai jun kikanshi, 24, 305 Hill, 2013, Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series, Clin Toxicol (Phila), 51, 487, 10.3109/15563650.2013.802795 Rose, 2013, A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug, Clin Toxicol (Phila), 51, 174, 10.3109/15563650.2013.772191 Graudins, 1998, Treatment of the serotonin syndrome with cyproheptadine, J Emerg Med, 16, 615, 10.1016/S0736-4679(98)00057-2 Thanacoody, 2012, Serotonin syndrome, Medicine, 40, 63, 10.1016/j.mpmed.2011.11.005 Mackay, 1999, Antidepressants and the serotonin syndrome in general practice, Br J Gen Pract, 49, 871 Tatsumi, 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters, Eur J Pharmacol, 340, 249, 10.1016/S0014-2999(97)01393-9 Ringland, 2008, Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data, Br J Clin Pharmacol, 66, 682 Pilgrim, 2011, Deaths involving contraindicated and inappropriate combinations of serotonergic drugs, Int J Legal Med, 125, 803, 10.1007/s00414-010-0536-3 Serotonin, 1958, (5-hydroxytryptamine); the last four years, Physiol Rev, 38, 277, 10.1152/physrev.1958.38.2.277 Udenfriend, 1957, Increase in tissue serotonin following administration of its precursor 5-hydroxytryptophan, J Biol Chem, 224, 803, 10.1016/S0021-9258(18)64972-5 Hwang, 1979, Behavioral and biochemical actions of p-chlorophenylethylamine (p-CPEA) in mice, Life Sci, 24, 595, 10.1016/0024-3205(79)90155-3 Green, 1976, Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine, Nature, 260, 487, 10.1038/260487a0 Erspamer, 1952, Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine, Nature, 169, 800, 10.1038/169800b0 Rapport, 1948, Serum vasoconstrictor, serotonin; isolation and characterization, J Biol Chem, 176, 1243, 10.1016/S0021-9258(18)57137-4 Lopez-Munoz, 2009, Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950 until today, Curr Pharm Des, 15, 1563, 10.2174/138161209788168001 Loizou, 1970, Uptake of monoamines into central neurones and the blood-brain barrier in the infant rat, Br J Pharmacol, 40, 800, 10.1111/j.1476-5381.1970.tb10656.x Bogdanski, 1958, Pharmacological studies with the serotonin precursor, 5-hydroxytryptophan, J Pharmacol Exp Ther, 122, 182 Brodie, 1958, An interpretation of the action of psychotropic drugs, Postgrad Med, 24, 296, 10.1080/00325481.1958.11692214 Shore, 1958, Effect of iproniazid on brain levels of norepinephrine and serotonin, Science, 127, 704, 10.1126/science.127.3300.704 Jacobs, 1974, Effect of two dopamine receptor blockers on a serotonin-mediated behavioral syndrome in rats, Eur J Pharmacol, 27, 363, 10.1016/0014-2999(74)90014-4 Jacobs, 1974, Evidence for the functional interaction of two central neurotransmitters, Psychopharmacologia, 39, 81, 10.1007/BF00421461 Jacobs, 1975, Brain stem and spinal cord mediation of a serotonergic behavioral syndrome, Brain Res, 100, 450, 10.1016/0006-8993(75)90500-4 Deakin, 1978, The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats, Br J Pharmacol, 64, 201, 10.1111/j.1476-5381.1978.tb17290.x Ortmann, 1980, The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats, Naunyn Schmiedebergs Arch Pharmacol, 311, 185, 10.1007/BF00510258 Shimomura, 1981, Backward walking induced by L-5-hydroxytryptophan in mice, Jpn J Pharmacol, 31, 39, 10.1254/jjp.31.39 Lucki, 1984, Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat, J Pharmacol Exp Ther, 228, 133 Kennett, 1985, Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone, Eur J Pharmacol, 119, 143, 10.1016/0014-2999(85)90290-0 Abdel-Fattah, 1995, 5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats, Pharmacol Biochem Behav, 52, 379, 10.1016/0091-3057(95)00122-D Dickinson, 1986, 5-Hydroxytryptamine-mediated behaviour in male and female rats, Neuropharmacology, 25, 771, 10.1016/0028-3908(86)90094-8 Finberg, 2002, Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours, Neuropharmacology, 43, 1110, 10.1016/S0028-3908(02)00216-2 Corne, 1967, A possible correlation between drug-induced hallucinations in man and a behavioural response in mice, Psychopharmacologia, 11, 65, 10.1007/BF00401509 Darmani, 1990, Do functional relationships exist between 5-HT1A and 5-HT2 receptors, Pharmacol Biochem Behav, 36, 901, 10.1016/0091-3057(90)90098-3 Peroutka, 1981, Two distinct central serotonin receptors with different physiological functions, Science, 212, 827, 10.1126/science.7221567 Corne, 1963, A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine, Br J Pharmacol, 20, 106 Darmani, 1990, Withdrawal from chronic treatment with (+/−)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice, Eur J Pharmacol, 186, 115, 10.1016/0014-2999(90)94066-7 Darmani, 1992, Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+/−)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin, J Pharmacol Exp Ther, 262, 692 Fox, 2010, Functional interactions between 5-HT2A and presynaptic 5-HT1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT), Br J Pharmacol, 159, 879, 10.1111/j.1476-5381.2009.00578.x Handley, 1982, Effects on the 5-hydroxytryptamine-induced head-twitch of drugs with selective actions on alpha1 and alpha2-adrenoceptors, Neuropharmacology, 21, 507, 10.1016/0028-3908(82)90040-5 Handley, 1986, Involvement of the locus coeruleus in the potentiation of the quipazine-induced head-twitch response by diazepam and beta-adrenoceptor agonists, Neuropharmacology, 25, 1315, 10.1016/0028-3908(86)90102-4 Handley, 1986, The modulation of head-twitch behaviour by drugs acting on beta-adrenoceptors: evidence for the involvement of both beta 1- and beta 2-adrenoceptors, Psychopharmacology (Berl), 88, 320, 10.1007/BF00180832 Heal, 1985, Intracerebroventricular administration of 5,7-dihydroxytryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors, Neuropharmacology, 24, 1201, 10.1016/0028-3908(85)90155-8 Heal, 1986, The influence of central noradrenergic function on 5-HT2-mediated head-twitch responses in mice: possible implications for the actions of antidepressant drugs, Psychopharmacology (Berl), 89, 414, 10.1007/BF02412113 Tadano, 1986, Head-twitches induced by p-hydroxyamphetamine in mice, Jpn J Pharmacol, 41, 519, 10.1254/jjp.41.519 Willins, 1997, Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats, J Pharmacol Exp Ther, 282, 699 Marley, 1984, Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake, J Psychiatr Res, 18, 173, 10.1016/0022-3956(84)90008-6 Marley, 1984, Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake, J Psychiatr Res, 18, 191, 10.1016/0022-3956(84)90009-8 Marley, 1985, Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine re-uptake, clomipramine, J Psychiatr Res, 19, 597, 10.1016/0022-3956(85)90079-2 Curzon, 1979, Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine, Br J Pharmacol, 66, 573, 10.1111/j.1476-5381.1979.tb13696.x Darmani, 1999, Long-term sequential determination of behavioral ontogeny of 5-HT1A and 5-HT2 receptor functions in the rat, J Pharmacol Exp Ther, 288, 247 Koshikawa, 1991, The effects of tianeptine on wet-dog shakes, fore-paw treading and a flexor reflex in rats are consistent with enhancement of 5-hydroxytryptamine uptake, Eur J Pharmacol, 198, 51, 10.1016/0014-2999(91)90561-4 Bedard, 1977, “Wet-dog” shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity, Neuropharmacology, 16, 663, 10.1016/0028-3908(77)90117-4 Koshikawa, 1985, Effects of antidepressant drug combinations on cortical 5-HT2 receptors and wet-dog shakes in rats, Eur J Pharmacol, 118, 273, 10.1016/0014-2999(85)90138-4 Koshikawa, 1989, Production of wet-dog shakes in rats and down-regulation of spinal 5-HT2 receptors, Eur J Pharmacol, 164, 595, 10.1016/0014-2999(89)90271-9 Nagayama, 1996, Circadian rhythm in the responsiveness of central 5-HT2A receptor to DOI in rats, Psychopharmacology (Berl), 127, 113, 10.1007/BF02805983 Speiser, 2008, Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline, J Neural Transm, 115, 107, 10.1007/s00702-007-0811-8 Yap, 1983, Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat, Neuropharmacology, 22, 801, 10.1016/0028-3908(83)90123-5 Grahame-Smith, 1971, Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan, J Neurochem, 18, 1053, 10.1111/j.1471-4159.1971.tb12034.x Nisijima, 2001, Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome, Brain Res, 890, 23, 10.1016/S0006-8993(00)03020-1 Shioda, 2010, Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome, Neurosci Lett, 482, 216, 10.1016/j.neulet.2010.07.039 Berendsen, 1990, Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice, Br J Pharmacol, 101, 667, 10.1111/j.1476-5381.1990.tb14138.x Zhang, 2009, Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome, Eur J Pharmacol, 615, 66, 10.1016/j.ejphar.2009.05.008 Diaz, 2011, Implication of 5-HT(2B) receptors in the serotonin syndrome, Neuropharmacology, 61, 495, 10.1016/j.neuropharm.2011.01.025 Nisijima, 2003, Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome, Neurochem Int, 43, 155, 10.1016/S0197-0186(02)00213-9 Nisijima, 2004, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome, Pharmacopsychiatry, 37, 57, 10.1055/s-2004-815526 Fox, 2008, Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice, Psychopharmacology (Berl), 201, 203, 10.1007/s00213-008-1268-7 Yamada, 1988, The involvement of serotonergic and dopaminergic systems in hypothermia induced in mice by intracerebroventricular injection of serotonin, Jpn J Pharmacol, 48, 145, 10.1254/jjp.48.145 Mazzola-Pomietto, 1995, Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors, Psychopharmacology (Berl), 117, 193, 10.1007/BF02245187 Gudelsky, 1986, Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors, Neuropharmacology, 25, 1307, 10.1016/0028-3908(86)90101-2 Morishima, 1995, Evidence that 5-HT2A receptors are not involved in 5-HT-mediated thermoregulation in mice, Pharmacol Biochem Behav, 52, 755, 10.1016/0091-3057(95)00172-S Fox, 2010, The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis, Psychopharmacology (Berl), 212, 13, 10.1007/s00213-009-1694-1 Goodwin, 1985, The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function, Neuropharmacology, 24, 1187, 10.1016/0028-3908(85)90153-4 Bill, 1991, Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia, Br J Pharmacol, 103, 1857, 10.1111/j.1476-5381.1991.tb12342.x Drust, 1983, Pharmacological analysis of shaking behavior induced by enkephalins, thyrotropin-releasing hormone or serotonin in rats: evidence for different mechanisms, J Pharmacol Exp Ther, 224, 148 Colpaert, 1989, 1-5-Hydroxytryptophan-induced flat body posture in the rat: antagonism by ritanserin and potentiation after 5,7-dihydroxytryptamine, Eur J Pharmacol, 169, 175, 10.1016/0014-2999(89)90830-3 Izumi, 2006, Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats, Eur J Pharmacol, 532, 258, 10.1016/j.ejphar.2005.12.075 Bert, 2006, Mice over-expressing the 5-HT(1A) receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT, Behav Brain Res, 167, 328, 10.1016/j.bbr.2005.09.020 Blanchard, 1997, An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome, Pharmacol Biochem Behav, 57, 897, 10.1016/S0091-3057(96)00472-8 Fernando, 1980, Differential antagonism by neuroleptics of backward-walking and other behaviours caused by amphetamine at high dosage, Neuropharmacology, 19, 549, 10.1016/0028-3908(80)90025-8 Blanchard, 1993, An ethopharmacological analysis of the behavioral effects of 8-OH-DPAT, Psychopharmacology (Berl), 112, 55, 10.1007/BF02247363 Fox, 2007, Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice, Neuropharmacology, 53, 643, 10.1016/j.neuropharm.2007.07.009 Izumi, 2007, Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats, Eur J Pharmacol, 565, 105, 10.1016/j.ejphar.2007.02.059 Grahame-Smith, 1971, Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor, Br J Pharmacol, 43, 856, 10.1111/j.1476-5381.1971.tb07222.x Sloviter, 1978, Evidence that serotonin mediates some behavioral effects of amphetamine, J Pharmacol Exp Ther, 206, 348 Goodwin, 1986, The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism, Psychopharmacology (Berl), 90, 488, 10.1007/BF00174066 Matthews, 1980, Pharmacological profile of a model for central serotonin receptor activation, Life Sci, 26, 1397, 10.1016/0024-3205(80)90042-9 Fox, 2009, Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice, Int J Neuropsychopharmacol, 12, 1055, 10.1017/S146114570900011X Fox, 2012, Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans, Pharmacogen J Gwaltney-Brant, 2000, 5-Hydroxytryptophan toxicosis in dogs: 21 cases (1989–1999), J Am Vet Med Assoc, 216, 1937, 10.2460/javma.2000.216.1937 Carruba, 1979, Evidence for a receptor supersensitivity following impairment of central serotoninergic activity in the rabbit, Naunyn Schmiedebergs Arch Pharmacol, 309, 125, 10.1007/BF00501219 Volkman, 1978, L-5-Hydroxytryptophan-induced myoclonus in guinea pigs: a model for the study of central serotonin-dopamine interactions, Neuropharmacology, 17, 947, 10.1016/0028-3908(78)90137-5 Luscombe, 1981, Pharmacological analysis of the myoclonus induced by 5-hydroxytryptophan in the guinea pig suggests the presence of multiple 5-hydroxytryptamine receptors in the brain, Neuropharmacology, 20, 819, 10.1016/0028-3908(81)90074-5 Eison, 1992, 5-HT1A and 5-HT2 receptors mediate discrete behaviors in the Mongolian gerbil, Pharmacol Biochem Behav, 43, 131, 10.1016/0091-3057(92)90649-Z Darmani, 1998, Production of serotonin syndrome by 8-OH DPAT in Cryptotis parva, Physiol Behav, 65, 327, 10.1016/S0031-9384(98)00174-7 Curzon, 1963, The biochemical, behavioral, and neurologic effects of high Ltryptophan intake in the rhesus monkey, Neurology, 13, 431, 10.1212/WNL.13.5.431 Mizuta, 1990, Behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in monkeys, Eur J Pharmacol, 178, 125, 10.1016/0014-2999(90)94804-7 Taffe, 2006, Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys, Drug Alcohol Depend, 82, 276, 10.1016/j.drugalcdep.2005.09.013 Yamada, 1987, Pharmacological analysis of the variation in behavioural responses to tryptamine in five strains of mice, Eur J Pharmacol, 140, 323, 10.1016/0014-2999(87)90289-5 Stewart, 1976, Myoclonus after 5-hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system, Neurology, 26, 690, 10.1212/WNL.26.7.690 Goodwin, 1985, A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors, Br J Pharmacol, 84, 743, 10.1111/j.1476-5381.1985.tb16157.x Goodwin, 1987, The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), Psychopharmacology (Berl), 91, 506, 10.1007/BF00216019 Green, 1984, The behavioural effects of RU 24969, a suggested 5-HT1 receptor agonist in rodents and the effect on the behaviour of treatment with antidepressants, Neuropharmacology, 23, 655, 10.1016/0028-3908(84)90147-3 Lu, 1996, Circadian rhythm in the response of central 5-HT1A receptors to 8-OH-DPAT in rats, Psychopharmacology (Berl), 123, 42, 10.1007/BF02246279 Lu, 1997, Circadian rhythm in the function of central 5-HT1A receptors is endogenous in nature, Cell Mol Life Sci, 53, 224, 10.1007/PL00000594 Smith, 1986, Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome, Pharmacol Biochem Behav, 24, 1513, 10.1016/0091-3057(86)90477-6 Assie, 2010, F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity, Int J Neuropsychopharmacol, 1 Forster, 1995, A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635, Eur J Pharmacol, 281, 81, 10.1016/0014-2999(95)00234-C Sprouse, 2004, 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production, Neuropharmacology, 46, 52, 10.1016/j.neuropharm.2003.08.007 Tricklebank, 1984, The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat, Eur J Pharmacol, 106, 271, 10.1016/0014-2999(84)90714-3 Roth, 1997, Pharmacology of 5-HT2 receptors, 367 Arnt, 1989, Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI, Eur J Pharmacol, 161, 45, 10.1016/0014-2999(89)90178-7 Cowen, 1982, beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses, Br J Pharmacol, 76, 265, 10.1111/j.1476-5381.1982.tb09216.x Nimgaonkar, 1983, Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat, Neuropharmacology, 22, 739, 10.1016/0028-3908(83)90098-9 Green, 1981, A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure–activity requirements for the agonists, Br J Pharmacol, 73, 703, 10.1111/j.1476-5381.1981.tb16806.x Green, 1983, Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone, Neuropharmacology, 22, 573, 10.1016/0028-3908(83)90147-8 Sloviter, 1978, Specificity of a rat behavioral model for serotonin receptor activation, J Pharmacol Exp Ther, 206, 339 Nagayama, 1997, Circadian rhythm in the response to intracerebroventricular administration of 8-OH-DPAT, Brain Res, 756, 92, 10.1016/S0006-8993(97)00121-2 Koenig, 1988, 5-Hydroxytryptamine1A receptor-mediated effects of buspirone, gepirone and ipsapirone, Pharmacol Biochem Behav, 29, 711, 10.1016/0091-3057(88)90192-X Hjorth, 1985, Hypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT, J Neural Transm, 61, 131, 10.1007/BF01253058 Dalpiaz, 1995, Binding thermodynamics of serotonin to rat-brain 5-HT1A, 5HT2A and 5-HT3 receptors, Life Sci, 57, PL141, 10.1016/0024-3205(95)02072-Q Peroutka, 1979, Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol, Mol Pharmacol, 16, 687 Squires, 2007, Serotonin catabolism in the central and enteric nervous systems of rats upon induction of serotonin syndrome, J Neurochem, 103, 174 Yamada, 1988, The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice, Eur J Pharmacol, 154, 299, 10.1016/0014-2999(88)90205-1 Dursun, 1993, The effects of alpha 2-adrenoceptor antagonists on the inhibition of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head shakes by 5-HT1A receptor agonists in the mouse, Br J Pharmacol, 109, 1046, 10.1111/j.1476-5381.1993.tb13727.x Gonzalez-Maeso, 2007, Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior, Neuron, 53, 439, 10.1016/j.neuron.2007.01.008 Goodwin, 1984, 5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice, Br J Pharmacol, 83, 235, 10.1111/j.1476-5381.1984.tb10140.x Moya, 2007, Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors, J Pharmacol Exp Ther, 321, 1054, 10.1124/jpet.106.117507 Kitamura, 1994, Buspirone enhances head twitch behavior in mice, Eur J Pharmacol, 253, 297, 10.1016/0014-2999(94)90206-2 Darmani, 2004, Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis, Eur J Pharmacol, 488, 201, 10.1016/j.ejphar.2004.02.018 Darmani, 1996, The mechanism by which the selective 5-HT1A receptor antagonist S-(−) UH 301 produces head-twitches in mice, Pharmacol Biochem Behav, 55, 1, 10.1016/0091-3057(96)00072-X Endo, 1985, Evidence that the accumulation of 5-hydroxytryptamine in the liver but not in the brain may cause the hypoglycaemia induced by 5-hydroxytryptophan, Br J Pharmacol, 85, 591, 10.1111/j.1476-5381.1985.tb10553.x Modigh, 1972, Central and peripheral effects of 5-hydroxytryptophan on motor activity in mice, Psychopharmacologia, 23, 48, 10.1007/BF00414413 Modigh, 1973, Effects of chlorimipramine and protriptyline on the hyperactivity induced by 5-hydroxytryptophan after peripheral decarboxylase inhibition in mice, J Neural Transm, 34, 101, 10.1007/BF01244663 Yamada, 1995, Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice, Biol Pharm Bull, 18, 1580, 10.1248/bpb.18.1580 Guscott, 2003, The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor, Neuropharmacology, 44, 1031, 10.1016/S0028-3908(03)00117-5 Sugimoto, 2001, Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice, Eur J Pharmacol, 430, 265, 10.1016/S0014-2999(01)01386-3 Yamada, 1987, Hypothermia induced in mice by intracerebroventricular injection of tryptamine: involvement of the 5-HT1 receptor, Eur J Pharmacol, 139, 117, 10.1016/0014-2999(87)90505-X Sugimoto, 1991, Activation of peripheral serotonin2 receptors induces hypothermia in mice, Life Sci, 48, 419, 10.1016/0024-3205(91)90497-Y Hegerl, 1998, The serotonin syndrome scale: first results on validity, Eur Arch Psychiatry Clin Neurosci, 248, 96, 10.1007/s004060050024 Ma, 2013, Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats, J Neurochem, 10.1111/jnc.12141 Nisijima, 2000, Risperidone counteracts lethality in an animal model of the serotonin syndrome, Psychopharmacology (Berl), 150, 9, 10.1007/s002130000397 Bilbey, 1960, The anatomical basis of the straub phenomenon, Br J Pharmacol Chemother, 15, 540, 10.1111/j.1476-5381.1960.tb00277.x Pardo-Lozano, 2012, Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): the influence of gender and genetics (CYP2D6, COMT, 5-HTT), PloS one, 7, e47599, 10.1371/journal.pone.0047599 Butler, 2008, Free drug metabolic clearance in elderly people, Clin Pharmacokinet, 47, 297, 10.2165/00003088-200847050-00002 McLean, 2004, Aging biology and geriatric clinical pharmacology, Pharmacol Rev, 56, 163, 10.1124/pr.56.2.4 Mitsch, 2013, Antidepressant adverse drug reactions in older adults: implications for RNs and APNs, Geriatr Nurs, 34, 53, 10.1016/j.gerinurse.2012.08.004 Murphy, 2008, How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems, Neuropharmacology, 55, 932, 10.1016/j.neuropharm.2008.08.034 Pilgrim, 2011, Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects, Forensic Sci Med Pathol, 7, 162, 10.1007/s12024-010-9188-3 Vizcaychipi, 2007, Serotonin syndrome triggered by tramadol, Br J Anaesth, 99, 919, 10.1093/bja/aem325 Kesavan, 1999, Serotonin syndrome with fluoxetine plus tramadol, J Roy Soc Med, 92, 474, 10.1177/014107689909200915 Asch, 1988, The Libby Zion case. One step forward or two steps backward?, N Engl J Med, 318, 771, 10.1056/NEJM198803243181209 Kaneda, 2001, Possible mild serotonin syndrome related to co-prescription of tandospirone and trazodone, Gen Hosp Psychiatry, 23, 98, 10.1016/S0163-8343(01)00125-6 Tamura, 2002, Serotonin syndrome caused by tandospirone citrate alone, Rinsho shinkeigaku, 42, 892 Turner, 2006, Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan, Pharmacol Thera, 109, 325, 10.1016/j.pharmthera.2005.06.004 Beaune, 2012, Mechanisms of high-dose citalopram-induced death in a rat model, Toxicology, 302, 248, 10.1016/j.tox.2012.08.006 Berendsen, 1989, Selective activation of 5HT1A receptors induces lower lip retraction in the rat, Pharmacol Biochem Behav, 33, 821, 10.1016/0091-3057(89)90477-2 Boban Blagaic, 2005, Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats, Eur J Pharmacol, 512, 173, 10.1016/j.ejphar.2005.02.033 Costain, 1978, beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine, Br J Pharmacol, 64, 193, 10.1111/j.1476-5381.1978.tb17289.x Cuadra, 1989, Different behavioral reactivity of 5-HT1 sites between killer and non-killer rats after midbrain raphe lesion, Acta Physiol Pharmacol Latinoam, 39, 91 Goodwin, 1987, Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat, Psychopharmacology (Berl), 91, 500, 10.1007/BF00216018 Green, 1978, Repeated exposure of rats to the convulsant agent flurothyl enhances 5-hydroxytryptamine- and dopamine-mediated behavioural responses, Br J Pharmacol, 62, 325, 10.1111/j.1476-5381.1978.tb08464.x Green, 1980, Brain noradrenaline depletion prevents ECS-induced enhancement of serotonin- and dopamine-mediated behaviour, Nature, 285, 232, 10.1038/285232a0 Green, 1974, The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats, Neuropharmacology, 13, 949, 10.1016/0028-3908(74)90086-0 Green, 1974, TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats, Nature, 251, 524, 10.1038/251524a0 Green, 1976, (−)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system, Nature, 262, 594, 10.1038/262594a0 Green, 1975, The concentration of 5-methoxytryptamine in rat brain and its effects on behaviour following its peripheral injection, Neuropharmacology, 14, 601, 10.1016/0028-3908(75)90127-6 Green, 1975, Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration, Br J Pharmacol, 55, 415, 10.1111/j.1476-5381.1975.tb06946.x Green, 1976, Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour, Neuropharmacology, 15, 173, 10.1016/0028-3908(76)90026-5 Hillegaart, 1989, Effects of 8-OH-DPAT on motor activity in the rat, Pharmacol Biochem Behav, 32, 797, 10.1016/0091-3057(89)90036-1 Kleven, 1997, Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats, J Pharmacol Exp Ther, 282, 747 Krishnamoorthy, 2010, Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain, Basic Clin Pharmacol Toxicol, 107, 830, 10.1111/j.1742-7843.2010.00586.x Lucki, 1982, Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants, Psychopharmacology (Berl), 77, 205, 10.1007/BF00464567 Marsden, 1978, The contribution of tryptamine to the behavioural effects of L-tryptophan in tranylcypromine-treated rats, Psychopharmacology (Berl), 57, 71, 10.1007/BF00426960 Nagayama, 1998, Circadian and circannual rhythms in the function of central 5-HT1A receptors in laboratory rats, Psychopharmacology (Berl), 135, 279, 10.1007/s002130050510 Ortmann, 1981, Interaction of beta-adrenoceptor agonists with the serotonergic system in rat brain. A behavioral study using the L-5-HTP syndrome, Naunyn Schmiedebergs Arch Pharmacol, 316, 225, 10.1007/BF00505653 Osei-Owusu, 2005, 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome, J Pharmacol Exp Ther, 313, 1324, 10.1124/jpet.104.082073 Shioda, 2004, Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine, Prog Neuropsychopharmacol Biol Psychiatry, 28, 633, 10.1016/j.pnpbp.2004.01.013 Trulson, 1976, Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine, J Pharmacol Exp Ther, 198, 23 Trulson, 1976, Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine, Eur J Pharmacol, 36, 149, 10.1016/0014-2999(76)90266-1 Van Oekelen, 2002, Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats, Behav Pharmacol, 13, 313, 10.1097/00008877-200207000-00008 Kreilgaard, 2008, Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice, Br J Pharmacol, 155, 276, 10.1038/bjp.2008.243 Yamada, 1987, The behavioural effects of intravenously administered tryptamine in mice, Neuropharmacology, 26, 49, 10.1016/0028-3908(87)90043-8 Radomski, 2000, An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria, Med Hypotheses, 55, 218, 10.1054/mehy.2000.1047 Ortmann, 1981, Supersensitivity to L-5-hydroxytryptophan after 5,7-dihydroxytryptamine injections in desmethylimipramine- and nomifensine-pretreated rats: behavioral evidence for postsynaptic supersensitivity, Psychopharmacology (Berl), 74, 109, 10.1007/BF00432674 Deakin, 1981, The differential neurochemical bases of the behaviours elicited by serotonergic agents and by the combination of a monoamine oxidase inhibitor and L-DOPA, Neuropharmacology, 20, 123, 10.1016/0028-3908(81)90194-5 Tricklebank, 1985, Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat, Eur J Pharmacol, 117, 15, 10.1016/0014-2999(85)90467-4 Stewart, 1976, 5-Hydroxytryptophan-induced myoclonus: increased sensitivity to serotonin after intracranial 5,7-dihydroxytryptamine in the adult rat, Neuropharmacology, 15, 449, 10.1016/0028-3908(76)90054-X Green, 1980, Enhanced 5-hydroxytryptamine and dopamine-mediated behavioural responses following convulsions – III. The effects of monoamine antagonists and synthesis inhibitors on the ability of electroconvulsive shock to enhance responses, Neuropharmacology, 19, 907, 10.1016/0028-3908(80)90092-1 Moore, 1993, 5-HT1A-mediated lower lip retraction: effects of 5-HT1A agonists and antagonists, Pharmacol Biochem Behav, 46, 141, 10.1016/0091-3057(93)90330-V Yamada, 1989, The evidence for the involvement of the 5-HT1A receptor in 5-HT syndrome induced in mice by tryptamine, Jpn J Pharmacol, 51, 421, 10.1254/jjp.51.421 Nagata, 1991, Veratramine-induced behavior associated with serotonergic hyperfunction in mice, Jpn J Pharmacol, 55, 129, 10.1254/jjp.55.129